Updated 3/28/2025. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.
| Manufacturer Sort descending | Labeler Codes Reviewed | State | OPA Findings | Sanction | Corrective Action Status |
|---|---|---|---|---|---|
| Cycle Pharmaceuticals, Ltd. | 70709 | MA |
Cycle did not determine the difference between the new drug estimate and the actual 340B ceiling price and offer a refund. |
Repayment to covered entities |
Pending |
Rhodes Pharmaceuticals LPContact InformationDirector, Pricing Operations |
42858 59011 72912 |
NC |
Rhodes charged more than the 340B ceiling price. |
Repayment to covered entities |
CAP approved |